Leora Horn

54.9k total citations · 1 hit paper
128 papers, 4.3k citations indexed

About

Leora Horn is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Leora Horn has authored 128 papers receiving a total of 4.3k indexed citations (citations by other indexed papers that have themselves been cited), including 106 papers in Oncology, 84 papers in Pulmonary and Respiratory Medicine and 20 papers in Cancer Research. Recurrent topics in Leora Horn's work include Lung Cancer Treatments and Mutations (76 papers), Cancer Immunotherapy and Biomarkers (63 papers) and Lung Cancer Research Studies (30 papers). Leora Horn is often cited by papers focused on Lung Cancer Treatments and Mutations (76 papers), Cancer Immunotherapy and Biomarkers (63 papers) and Lung Cancer Research Studies (30 papers). Leora Horn collaborates with scholars based in United States, Spain and France. Leora Horn's co-authors include Scott Gettinger, Emily Castellanos, Scott Antonia, David R. Spigel, Emily Feld, Julie R. Brahmer, Matthew D. Hellmann, Lecia V. Sequist, Ang Li and Rebecca S. Heist and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Leora Horn

124 papers receiving 4.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

2018 539 citations Scott Gettinger, Leora Horn et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Leora Horn

Since Specialization

Citations

This map shows the geographic impact of Leora Horn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leora Horn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leora Horn more than expected).

Fields of papers citing papers by Leora Horn

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leora Horn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leora Horn. The network helps show where Leora Horn may publish in the future.

Co-authorship network of co-authors of Leora Horn

This figure shows the co-authorship network connecting the top 25 collaborators of Leora Horn. A scholar is included among the top collaborators of Leora Horn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leora Horn. Leora Horn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tumor DNA 2022 ·Lung Cancer ·Thomas E. Stinchcombe, Xiaofei Wang, Robert C. Doebele, Leylah Drusbosky, David E. Gerber, Leora Horn, Erin M. Bertino, Geoffrey Liu, Liza C. Villaruz, D. Ross Camidge	1
2	Associations of influenza vaccination with severity of immune-related adverse events in patients with advanced thoracic cancers on immune checkpoint inhibitors 2022 ·ERJ Open Research ·(unknown), Li‐Ching Huang, Jennifer G. Whisenant, Sally J. York, Travis Osterman, Jennifer A. Lewis, Wade T. Iams, (unknown), (unknown), Chih–Yuan Hsu, Yu Shyr, Leora Horn	1
3	Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC 2020 ·Journal of Thoracic Oncology ·Thomas E. Stinchcombe, Robert C. Doebele, Xiaofei Wang, David E. Gerber, Leora Horn, D. Ross Camidge	21
4	Ensartinib (X-396) in ALK-Positive Non–Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study 2018 ·Clinical Cancer Research ·Leora Horn, Jeffrey R. Infante, Karen L. Reckamp, George R. Blumenschein, Ticiana Leal, Saiama N. Waqar, Barbara J. Gitlitz, Rachel E. Sanborn, Jennifer G. Whisenant, Liping Du, Joel W. Neal, Jon P. Gockerman, Gary Dukart, Kimberly Harrow, Chris Liang, James J. Gibbons, (unknown), Christine M. Lovly, Heather A. Wakelee	131
5	Stage 2 enrollment complete: Sitravatinib in combination with nivolumab in NSCLC patients progressing on prior checkpoint inhibitor therapy 2018 ·Annals of Oncology ·(unknown), Alexander I. Spira, Collin M. Blakely, Kai He, David Berz, Donald Richards, (unknown), Abigail L. Savage, (unknown), Erminia Massarelli, Robert M. Jotte, (unknown), James G. Christensen, Peter Olson, Vanessa Tassell, Leora Horn	9
6	Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer 2018 ·Lung Cancer ·Leora Horn, Joshua Bauml, Patrick M. Forde, Keith L. Davis, Nathaniel J. Myall, Medha Sasané, Anand A. Dalal, (unknown), Antoinette J. Wozniak, Christina S. Baik, Alex Mutebi, Pingkuan Zhang, Heather A. Wakelee, Bruce E. Johnson	12
7	Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan 2017 ·Journal of Clinical Oncology ·Rebecca S. Heist, Michael J. Guarino, Gregory A. Masters, W. Thomas Purcell, Alexander Starodub, Leora Horn, Ronald Scheff, Aditya Bardia, Wells A. Messersmith, Jordan Berlin, Allyson J. Ocean, Serengulam V. Govindan, Pius Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, David M. Goldenberg, D. Ross Camidge	139
8	CNS activity of ensartinib in ALK+ non-small cell lung cancer (NSCLC) patients (pts) 2017 ·Annals of Oncology ·Karen L. Reckamp, Heather A. Wakelee, Sandip Pravin Patel, George R. Blumenschein, Joel W. Neal, Barbara J. Gitlitz, Saiama N. Waqar, (unknown), Kimberly Harrow, Leora Horn	3
9	OA03.05 Analysis of Early Survival in Patients with Advanced Non-Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057 2017 ·Journal of Thoracic Oncology ·Solange Peters, Federico Cappuzzo, Leora Horn, Luis Paz‐Ares, Hossein Borghaei, Fabrice Barlési, Martin Steins, Enriqueta Felip, David R. Spigel, Cécile Dorange, Haolan Lu, Diane Healey, (unknown), Prabhu Bhagavatheeswaran, James Novotny, Brian Lestini, Julie R. Brahmer	37
10	Response to salvage chemotherapy following exposure to PD-1/PD-L1 inhibitors in patients with NSCLC 2017 ·Annals of Oncology ·Sacha I. Rothschild, Paul Leger, (unknown), Rathi N. Pillai, Sally J. York, Leora Horn	8
11	Three-year follow-up from CheckMate 017/057: Nivolumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) 2017 ·Annals of Oncology ·E. Felip Font, Scott Gettinger, (unknown), Scott Antonia, Esther Holgado, David R. Spigel, Óscar Arrieta, M. Dómine Gómez, Osvaldo Arén Frontera, Julie R. Brahmer, Laura Q.M. Chow, Lucio Crinò, Charles Butts, Bruno Coudert, Leora Horn, Martin Steins, William J. Geese, A. Li, Diane Healey, Everett E. Vokes	22
12	Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives 2017 ·OncoTargets and Therapy ·Emily Feld, Leora Horn	3
13	NSCLC, metastatic CheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC 2016 ·Annals of Oncology ·Mark A. Socinski, Ben Creelan, Leora Horn, Martin Reck, Luis Paz‐Ares, Martin Steins, Enriqueta Felip, Michel M. van den Heuvel, Tudor–Eliade Ciuleanu, Firas Badin, Neal Ready, T. Jeroen N. Hiltermann, Suresh Nair, Rosalyn A. Juergens, Solange Peters, Elisa Minenza, William J. Geese, Prabhu Bhagavatheeswaran, (unknown), David P. Carbone	86
14	PS01.62: Long-Term Safety and Clinical Activity of Atezolizumab Monotherapy in Metastatic NSCLC: Final Results from a Phase Ia Study 2016 ·Journal of Thoracic Oncology ·Michael S. Gordon, Roy S. Herbst, Leora Horn, Jean‐Charles Soria, Leena Gandhi, Enriqueta Felip, Lecia V. Sequist, David R. Spigel, Scott Antonia, Ani Sarkis Balmanoukian, Philippe A. Cassier, Bo Liu, Marcin Kowanetz, Carol O’Hear, Marcella Fassò, Alan Sandler, Scott Gettinger	2
15	Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction 2016 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), Romany Johnpulle, Igor Puzanov, Leora Horn, Alicia K. Morgans, Jeffrey A. Sosman, Suthee Rapisuwon, Robert M. Conry, Zeynep Eroglu, Douglas B. Johnson	60
16	Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant EGFR -Mutant Lung Cancer with and without T790M Mutations 2014 ·Cancer Discovery ·Yelena Y. Janjigian, Egbert F. Smit, Harry J.M. Groen, Leora Horn, Scott Gettinger, D. Ross Camidge, Gregory J. Riely, Bushi Wang, Yali Fu, Vikram K. Chand, Vincent A. Miller, William Pao	295
17	A Patient With Metastatic Lung Adenocarcinoma Harboring ConcurrentEGFRL858R,EGFRGermline T790M, andPIK3CAMutations: The Challenge of Interpreting Results of Comprehensive Mutational Testing in Lung Cancer 2014 ·Journal of the National Comprehensive Cancer Network ·Philip E. Lammers, Christine M. Lovly, Leora Horn	10
18	Patient Enrollment onto Clinical Trials: the Role of Physician Knowledge 2013 ·Journal of Cancer Education ·Justin R. Gregg, Leora Horn, Mario Davidson, Jill Gilbert	2
19	Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung Cancer 2011 ·The Cancer Journal ·J. M. Andrews, Paul G. Yeh, William Pao, Leora Horn	24
20	Docetaxel in Non-Small Cell Lung Cancer 2007 ·Drugs & Aging ·Leora Horn, A. Visbal, Natasha B. Leighl	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact